Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

While the 23andMe acquisition isn't a reason to buy Regeneron, the stock's recently depressed price makes it worth a closer look. The company's former top-selling treatment, Eylea, is losing ...

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led ...

Genetic testing company 23andMe can proceed with a $305 million sale to the company’s co-founder Anne Wojcicki after a U.S.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Anne Wojcicki’s bid to buy 23andMe, the genetic testing company she co-founded nearly 20 years ago, has received the court ...

On May 19, Regeneron agreed to acquire 23andMe for $256 million. The potential acquisition is still subject to bankruptcy court approval. At its peak, 23andMe's market value swelled to $5.8 ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder ...